Tectonic Therapeutic Inc Stock Price, News & Analysis

Tectonic Therapeutic (NASDAQ: TECX) announced positive topline Phase 1b Part B results for TX45 in patients with Group 2 pulmonary hypertension associated with HFrEF on October 29, 2025. In 14 enrolled patients a single IV dose produced meaningful hemodynamic improvements including PCWP -29.2%, TPR -29.2%, mPAP -19.3% and CO +17.3%, with echocardiography showing persistent gains at day 29 (LVEF +19.4%, RVFAC +20.3%, TAPSE/SPAP +36.3%). TX45 was well tolerated with no serious or severe adverse events reported. Results support potential expansion into PH‑HFrEF while the company continues the APEX Phase 2 trial with topline 2026 readout expected.

Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company specializing in GPCR-focused therapeutic proteins and antibodies, has announced its participation in three major healthcare investor conferences in September 2025.

The company will attend the Wells Fargo Healthcare Conference on September 3 for investor meetings, the Cantor Global Healthcare Conference on September 4 featuring a fireside chat with CFO Daniel Lochner and CBO Marc Schwabish, and the Morgan Stanley Global Healthcare Conference on September 10 with CEO Alise Reicin. Both fireside chats will be webcast and available for replay on the company's website.

Tectonic Therapeutic (NASDAQ: TECX) reported Q2 2025 financial results and provided key clinical updates. The company ended Q2 with $287.4 million in cash, projecting runway into Q4'2028. Notable developments include plans to initiate a Phase 2 trial for TX45 in PH-ILD in 2026, completion of enrollment in TX45 Phase 1b Part B trial for PH-HFrEF, and continued enrollment in the TX45 APEX Phase 2 trial.

Complete results from TX45 Phase 1b Part A showed promising outcomes, including a 19% reduction in pulmonary capillary wedge pressure and 18.5% improvement in cardiac output. The company's pipeline expansion includes TX2100, targeting hereditary hemorrhagic telangiectasia, with Phase 1 trial initiation expected in Q1'2026.

Q2 2025 financial results showed R&D expenses of $17.2 million and a net loss of $20.0 million, reflecting increased investment in clinical development.

Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company specializing in therapeutic proteins and antibodies for GPCR modulation, has been added to the Russell 3000® Index following the 2025 Russell US Indexes annual reconstitution, effective June 30, 2025.

The inclusion automatically places Tectonic in either the Russell 1000® Index or Russell 2000® Index, along with corresponding growth and value style indexes. The Russell 3000® Index membership, which is determined by market capitalization rankings and style attributes, will remain in place for one year.

Tectonic Therapeutic (NASDAQ: TECX) announced complete results from Part A of their Phase 1b clinical trial for TX45, their lead asset and long-acting relaxin therapy, in treating Group 2 Pulmonary Hypertension in Heart Failure patients. The trial, involving 19 patients, demonstrated significant positive outcomes: • Single intravenous dose was well-tolerated with no serious adverse events • Achieved 19.0% reduction in pulmonary capillary wedge pressure • Showed >30% reduction in Pulmonary Vascular Resistance in CpcPH patients • Demonstrated sustained hemodynamic improvements for 29 days • Improved cardiac output (18.5% increase) and pulmonary hemodynamics The data supports TX45's potential as a best-in-class therapy for Group 2 pulmonary hypertension, with particularly strong benefits for CpcPH patients. The company expects topline data from Part B of the Phase 1b study in HFrEF patients in H2 2025.

Tectonic Therapeutic (NASDAQ: TECX) reported its Q1 2025 financial results and business updates. The company highlighted positive interim results from its TX45 Phase 1b Part A trial for PH-HFpEF patients, showing a 17.9% reduction in PCWP and >30% reduction in PVR for severe cases. The company successfully completed a $185 million PIPE financing in February 2025, strengthening its cash position to $306.2 million as of March 31, 2025, extending runway into Q4 2028. Tectonic initiated Part B of the TX45 Phase 1b trial in March 2025, with topline results expected in H2 2025. The company reported a net loss of $15.9 million for Q1 2025, with R&D expenses of $13.0 million and G&A expenses of $5.3 million. Full results from the Phase 1b Part A trial will be presented at the ESC Heart Failure Congress on May 17, 2025, while the APEX Phase 2 trial continues with results expected in 2026.

Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company specializing in therapeutic proteins and antibodies for GPCR modulation, has announced its participation in the Bank of America Securities 2025 Health Care Conference in Las Vegas. Dr. Alise Reicin, President and CEO, will deliver a corporate presentation on Thursday, May 15th, 2025, at 9:20am PDT.

The management team will be available for one-on-one meetings with investors during the conference. A live webcast will be accessible through the company's website, with a replay available for approximately 90 days after the event.

Tectonic Therapeutic (NASDAQ: TECX) has announced an upcoming late-breaking oral presentation at the European Society of Cardiology (ESC) Heart Failure 2025 Congress in Belgrade, Serbia. The presentation will showcase the complete Phase 1b results for TX45, the company's lead asset designed as a long-acting relaxin therapy for patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF).

The presentation, scheduled for May 17, 2025, will expand upon the interim data previously disclosed on January 30, 2025. Chief Development Officer Anthony Muslin, MD, will present the hemodynamic effects of TX45, which is being developed as a potential best-in-class therapy. The session will focus on late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension, and valvular heart disease.

Tectonic Therapeutic (NASDAQ: TECX) reported Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs. The company's TX45 Phase 1b trial showed promising interim results with a 17.9% reduction in Pulmonary Capillary Wedge Pressure in PH-HFpEF patients and over 30% reduction in Pulmonary Vascular Resistance in CpcPH patients.

Financial highlights include $141.2 million in cash and cash equivalents as of December 31, 2024, plus $185.0 million from a February 2025 private placement, extending cash runway into Q4'28. Q4 2024 saw increased R&D expenses of $9.2 million (vs $7.1M in Q4 2023) and net loss of $12.4 million (vs $7.9M in Q4 2023).

Key upcoming milestones include Phase 1b Part B results expected in 2H'25, APEX Phase 2 trial results in 2026, and TX2100 Phase 1 initiation for HHT treatment in Q4'25 or Q1'26.